{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:39:57Z","timestamp":1783453197778,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T00:00:00Z","timestamp":1123545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1038\/sj.bjc.6602732","type":"journal-article","created":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T17:07:46Z","timestamp":1123607266000},"page":"544-551","source":"Crossref","is-referenced-by-count":49,"title":["Prognostic impact of FAS\/CD95\/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression"],"prefix":"10.1038","volume":"93","author":[{"given":"K","family":"Yamana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Bilim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Itoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,9]]},"reference":[{"key":"BF6602732_CR1","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1002\/cncr.10549","volume":"94","author":"WV Bernstorff","year":"2002","unstructured":"Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS, Eberlein TJ (2002) Fas (CD95\/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 94: 2552\u20132560","journal-title":"Cancer"},{"key":"BF6602732_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ijc.10776","volume":"103","author":"VN Bilim","year":"2003","unstructured":"Bilim VN, Kasahara T, Hara N, Takahashi K, Tomita Y (2003) Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 103: 29\u201337","journal-title":"Int J Cancer"},{"key":"BF6602732_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1026472700554","volume":"2","author":"VN Bilim","year":"1997","unstructured":"Bilim VN, Tomita Y, Kawasaki T, Takeda M, Takahashi K (1997) Adriamycin (ADM) induced apoptosis in transitional cell cancer (TCC) cell lines accompanied by p21 WAF1\/CIP1 induction. Apoptosis 2: 207\u2013213","journal-title":"Apoptosis"},{"key":"BF6602732_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0002-9440(10)63910-7","volume":"162","author":"D Chopin","year":"2003","unstructured":"Chopin D, Barei-Moniri R, Maille P, Le Frere-Belda MA, Muscatelli-Groux B, Merendino N, Lecerf L, Stoppacciaro A, Velotti F (2003) Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 162: 1139\u20131149","journal-title":"Am J Pathol"},{"key":"BF6602732_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435\u20131448","journal-title":"Am J Surg Pathol"},{"key":"BF6602732_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nm0596-574","volume":"2","author":"C Friesen","year":"1996","unstructured":"Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1\/FAS) receptor\/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574\u2013577","journal-title":"Nat Med"},{"key":"BF6602732_CR7","doi-asserted-by":"publisher","first-page":"25428","DOI":"10.1074\/jbc.M302058200","volume":"278","author":"T Fukazawa","year":"2003","unstructured":"Fukazawa T, Walter B, Owen-Schaub LB (2003) Adenoviral Bid overexpression induces caspase-dependent cleavage of truncated Bid and p53-independent apoptosis in human non-small cell lung cancers. J Biol Chem 278: 25428\u201325434","journal-title":"J Biol Chem"},{"key":"BF6602732_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0014-5793(97)01282-9","volume":"417","author":"S Gamen","year":"1997","unstructured":"Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Pineiro A, Naval J (1997) Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 417: 360\u2013364","journal-title":"FEBS Lett"},{"key":"BF6602732_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00240-002-0274-1","volume":"30","author":"I Giannopoulou","year":"2002","unstructured":"Giannopoulou I, Nakopoulou L, Zervas A, Lazaris AC, Stravodimos C, Giannopoulos A, Davaris PS (2002) Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 30: 342\u2013345","journal-title":"Urol Res"},{"key":"BF6602732_CR10","first-page":"1794","volume":"8","author":"N Hara","year":"2002","unstructured":"Hara N, Kasahara T, Kawasaki T, Bilim VN, Obara K, Takahashi K, Tomita Y (2002) Reverse transcription\u2013polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 8: 1794\u20131799","journal-title":"Clin Cancer Res"},{"key":"BF6602732_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/40657","volume":"388","author":"M Irmler","year":"1997","unstructured":"Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388: 190\u2013195","journal-title":"Nature"},{"key":"BF6602732_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/sj.bjc.6601454","volume":"90","author":"T Itoi","year":"2004","unstructured":"Itoi T, Yamana K, Bilim VN, Takahashi K, Tomita Y (2004) Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer 90: 200\u2013205","journal-title":"Br J Cancer"},{"key":"BF6602732_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4161\/cbt.1.5.169","volume":"1","author":"MM Kelly","year":"2002","unstructured":"Kelly MM, Hoel BD, Voelkel-Johonson C (2002) Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with loss of c-FLIP expression. Cance Biol Ther 1: 520\u2013527","journal-title":"Cance Biol Ther"},{"key":"BF6602732_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<239::AID-IJC7>3.0.CO;2-S","volume":"84","author":"R Koomagi","year":"1999","unstructured":"Koomagi R, Volm M (1999) Expression of Fas (CD95\/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239\u2013243","journal-title":"Int J Cancer"},{"key":"BF6602732_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V94.1.265.413k37_265_274","volume":"94","author":"TH Landowski","year":"1999","unstructured":"Landowski TH, Shain KH, Oshiro MM, Buyuksal I, Painter JS, Dalton WS (1999) Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood 94: 265\u2013274","journal-title":"Blood"},{"key":"BF6602732_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1046\/j.1464-410x.1999.00975.x","volume":"83","author":"SH Lee","year":"1999","unstructured":"Lee SH, Lee JY, Park WS, Kim SY, Jang JJ, Yoo NJ (1999) Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int 83: 698\u2013702","journal-title":"BJU Int"},{"key":"BF6602732_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.urology.2003.08.023","volume":"63","author":"S Maas","year":"2004","unstructured":"Maas S, Warskulat U, Steinhoff C, Mueller W, Grimm MO, Schulz WA, Seifert HH (2004) Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology 63: 392\u2013397","journal-title":"Urology"},{"key":"BF6602732_CR18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/sj.bjc.6690202","volume":"79","author":"B Mann","year":"1999","unstructured":"Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C (1999) FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79: 1262\u20131269","journal-title":"Br J Cancer"},{"key":"BF6602732_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/bjc.1998.629","volume":"78","author":"GM Mead","year":"1998","unstructured":"Mead GM, Russell M, Clark P, Harland SJ, Harper PG, Cowan R, Roberts JT, Uscinska BM, Griffiths GO, Parmar MK (1998) A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78: 1067\u20131075","journal-title":"Br J Cancer"},{"key":"BF6602732_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ijc.10711","volume":"102","author":"G Mild","year":"2002","unstructured":"Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C (2002) DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 102: 254\u2013257","journal-title":"Int J Cancer"},{"key":"BF6602732_CR21","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W","volume":"79","author":"Y Mizutani","year":"1997","unstructured":"Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B (1997) Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 79: 1180\u20131189","journal-title":"Cancer"},{"key":"BF6602732_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","volume":"88","author":"S Nagata","year":"1997","unstructured":"Nagata S (1997) Apoptosis by death factor. Cell 88: 355\u2013365","journal-title":"Cell"},{"key":"BF6602732_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.184.3.1075","volume":"184","author":"J O'Connell","year":"1996","unstructured":"O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075\u20131082","journal-title":"J Exp Med"},{"key":"BF6602732_CR24","first-page":"3560","volume":"6","author":"K Okada","year":"2000","unstructured":"Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T (2000) Freaquency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin.Cancer Res 6: 3560\u20133564","journal-title":"Clin.Cancer Res"},{"key":"BF6602732_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0022-5347(17)39897-X","volume":"143","author":"CL Parsons","year":"1990","unstructured":"Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H (1990) Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 143: 139\u2013142","journal-title":"J Urol"},{"key":"BF6602732_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/25387","volume":"396","author":"RM Pitti","year":"1998","unstructured":"Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699\u2013703","journal-title":"Nature"},{"key":"BF6602732_CR27","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/eji.1830250821","volume":"25","author":"A Rensing-Ehl","year":"1995","unstructured":"Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A (1995) Local Fas\/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25: 2253\u20132258","journal-title":"Eur J Immunol"},{"key":"BF6602732_CR28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0094-0143(21)00412-2","volume":"19","author":"JY Ro","year":"1992","unstructured":"Ro JY, Staerkel GA, Ayala AG (1992) Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19: 435\u2013453","journal-title":"Urol Clin North Am"},{"key":"BF6602732_CR29","first-page":"2759","volume":"61","author":"W Roth","year":"2001","unstructured":"Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M (2001) Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61: 2759\u20132765","journal-title":"Cancer Res"},{"key":"BF6602732_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/ijc.11679","volume":"109","author":"B Schniewind","year":"2004","unstructured":"Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H (2004) Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109: 182\u2013188","journal-title":"Int J Cancer"},{"key":"BF6602732_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0090-4295(00)01008-6","volume":"57","author":"H Shimizu","year":"2001","unstructured":"Shimizu H, Akasaka S, Suzuki S, Akimoto M, Shimada T (2001) Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. Urology 57: 579\u2013584","journal-title":"Urology"},{"key":"BF6602732_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.cdd.4400813","volume":"8","author":"J Strater","year":"2001","unstructured":"Strater J, Walczak H, Hasel C, Melzner I, Leithauser F, Moller P (2001) CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ 8: 273\u2013278","journal-title":"Cell Death Differ"},{"key":"BF6602732_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/sj.leu.2403228","volume":"18","author":"A Suminoe","year":"2004","unstructured":"Suminoe A, Matsuzaki A, Hattori H, Koga Y, Kinukawa N, Ishii E, Hara T (2004) mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expression is an independent predictor for poor prognosis. Leukemia 18: 365\u2013368","journal-title":"Leukemia"},{"key":"BF6602732_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ijc.10956","volume":"104","author":"Y Tomita","year":"2003","unstructured":"Tomita Y, Bilim V, Hara N, Kasahara T, Takahashi K (2003) Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 104: 400\u2013408","journal-title":"Int J Cancer"},{"key":"BF6602732_CR35","first-page":"3331","volume":"57","author":"A Villunger","year":"1997","unstructured":"Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R (1997) Drug-induced apoptosis is associated with enhanced Fas (Apo-1\/CD95) ligand expression but occurs independently of Fas (Apo-1\/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 57: 3331\u20133334","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602732","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:17:39Z","timestamp":1684412259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF6602732"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602732","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,9]]}}}